Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
British Journal of Haematology|July 25, 2015
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxideDavid Sanford, Francesco Lo-Coco, Miguel A Sanz, et al.
American Journal of Hematology|June 26, 2012
Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemiaDi Sun, Paul Elson, Michaela Liedtke, et al.
Leukemia & Lymphoma|March 1, 2022
Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphomaTanya Siddiqi, Steven Coutre, Matthew McKinney, et al.
Blood|January 4, 2011
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodiesHolbrook E Kohrt, Roch Houot, Matthew J Goldstein, et al.
Blood|December 23, 2006
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisisJorge Cortes, Philippe Rousselot, Dong-Wook Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myelomaWei-Gang Tong, Rong Chen, William Plunkett, et al.
Blood|January 7, 2018
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapySteven Coutre, Michael Choi, Richard R Furman, et al.
Blood|August 14, 2010
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710Bayard L Powell, Barry Moser, Wendy Stock, et al.
The Lancet. Haematology|March 5, 2017
Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trialJeffrey A Jones, Tadeusz Robak, Jennifer R Brown, et al.
The Lancet. Oncology|October 19, 2012
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 studyHagop Kantarjian, Stefan Faderl, Guillermo Garcia-Manero, et al.
Pageof 5